Cogent Biosciences is a biotechnology company focused on developing therapies for genetically defined diseases. Co.'s approach is to design therapies that treat the underlying cause of disease and improve the lives of patients. Co.'s main program is bezuclastinib, also known as CGT9486, a highly selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. Bezuclastinib is a highly selective KIT inhibitor with the potential to provide a new treatment option for these patient populations. In addition, Co.'s research team is developing a portfolio of targeted therapies to help patients fighting serious, genetically driven diseases. The COGT stock yearly return is shown above.
The yearly return on the COGT stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the COGT annual return calculation with any dividends reinvested as applicable (on ex-dates).
|